Kongsberg

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with Chronic Obstructive Pulmonary Disease COPD who have a higher risk for heart and lung events. This Phase III study is randomized, double-blind, and conducted at multiple centers, focusing on participants with COPD and elevated cardiopulmonary risk. Participants will receive either the triple therapy inhaler or the dual therapy inhaler, both administered twice daily. The study compares these two inhalers over a period of up to three years, monitoring for serious cardiac or COPD events. The trial includes careful evaluation of various heart and lung-related health events during this period. During the study, participants will be closely monitored through regular visits, assessments, and tests to measure lung function, heart events, and COPD exacerbations. Researchers will track the time until the first severe cardiac or COPD event and evaluate other cardiovascular and respiratory outcomes over up to three years. Participants will also be assessed for their ability to properly use the inhaler and adherence to the study protocol throughout the trial.

Researchers are evaluating a complex intervention to improve advance care planning ACP for severely ill elderly people living at home who are acutely admitted to hospital. This cluster randomized study involves twelve Norwegian geriatric hospital units and aims to enhance patient and family involvement in treatment decisions, improve quality of life, and support ethical and legal care planning. The project also explores barriers and facilitators to implementing ACP at clinical, health service, and governmental levels, including economic analyses. The intervention group receives a comprehensive support program that includes leadership commitment, training for staff, implementation teams, ACP coordinators, and practical tools such as guidelines and documentation templates. The control group receives no implementation support during the trial but will be offered the program afterward. The study period includes baseline, 9-month, and 18-month assessments for the intervention group and baseline and 18-month assessments for the control group. Participants will undergo questionnaires and interviews with patients, relatives, clinicians, and staff at multiple time points before, during, and after the implementation. Data from patient records and national health registers will be collected to assess the fidelity of ACP implementation, clinical outcomes, communication quality, and cost-effectiveness. The trial runs until December 2026 and includes various measures to evaluate the impact of the support program on ACP delivery and related outcomes.

Researchers are evaluating if vision training can improve functional vision in people who have lost part of their visual field due to stroke. The study also aims to understand how vision training affects participants perception of their visual abilities and their ability to compensate for visual field loss in daily activities, especially related to driving. This trial compares home-based vision training to standard care without training. Participants are assigned to either immediate or delayed vision training groups. The training involves daily 20-minute home exercises using online and manual oculomotor activities, scanning, and visual search tasks over 8 weeks. Weekly phone calls help maintain motivation and provide support. The delayed group starts training 8 weeks after baseline, allowing comparison between immediate and postponed intervention effects. Throughout the study, participants will be assessed at baseline, and at multiple points after training, including 8 weeks and up to 28 weeks depending on the group. Researchers will measure visual field reaction times, reading speed, quality of life, occupational performance, and vision function using specialized tools. Participants are asked to keep a training diary and will be monitored for changes in functional vision and the ability to compensate for visual field loss. Total participation lasts from 20 to 28 weeks.